NCT00900198

Collection of Tissue Samples for Cancer Research

Recruiting now Last updated 14 April 2026

What this trial tests

trial testing Biopsy in Neoplasms in 5,000 participants. Currently enrolling.

Timeline

6 July 2006

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	6 July 2006
Sites	17 locations across Canada, United States

Drugs / interventions tested

• Biopsy — full drug profile →

Conditions studied

• Neoplasms — all drugs for Neoplasms →
• Lymphomas — all drugs for Lymphomas →
• Multiple Myeloma — all drugs for Multiple Myeloma →
• Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

National Cancer Institute (NCI)

Who can join

2 Months and older, any sex, with Neoplasms or Lymphomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.

Objectives:

* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
* To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.

Design:

* This is a multicenter tissue procurement protocol with NCI as the coordinating center.
* For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
* For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
* Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.
* This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
* Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
   Wang L, Balasubramanian P, Chen AP, Kummar S, et al · · 2016 · cited 98× · PMID 27663478 · DOI 10.1053/j.seminoncol.2016.06.004
2. Phenotyping and clinical utility of phagocytic polyploid giant cancer macrophages in blood.
   Adams DL, Cristofanilli M, Lin SH, Bergan RC, et al · · 2025 · cited 3× · PMID 40912599 · DOI 10.1016/j.canlet.2025.218007
3. MoSAIC: An Integrated and Modular Workflow for Confident Analysis of Protein Post-Translational Modification Landscapes.
   Xu Y, Chen L, Lih TM, Hu Y, et al · · 2026 · PMID 41453614 · DOI 10.1016/j.mcpro.2025.101502